Discovery Of Plant-Like Metabolic Pathway In Common Parasites Supplies New Targets For Therapy

June 25, 1998

Researchers from the United States and the United Kingdom have found that a group of parasites responsible for several devastating diseases -- including malaria -- share a metabolic pathway essential for survival in many plants, fungi and bacteria but not found in mammals. This finding provides many new targets for anti-parasitic medications, including the possibility of medicines related to currently available herbicides.

In the June 25 issue of the journal Nature, the researchers demonstrate that the herbicide glyphosate (Roundup), which interferes with the sixth of the initial seven enzymes in the plant-like pathway, inhibits in the test tube the growth of the parasites that cause malaria, toxoplasmosis and crytosporidiosis.

They also show that adding the herbicide to sub-therapeutic doses of a common anti-microbial medication can protect mice from otherwise fatal infections with Toxoplasma gondii. Similar tests against related parasites are planned.

"We urgently need new and better medicines to treat these extremely common diseases caused by parasites," said team leader Rima McLeod, M.D., the Jules and Doris Stein Research to Prevent Blindness Professor of Ophthalmology and Visual Sciences at the University of Chicago. Some of these diseases are untreatable at present because no known medicines inhibit them and others are caused by parasites that have developed resistance to available medicine. "These studies provide new, rational targets for development of novel treatments as well as several well-studied compounds that can interfere with this pathway."

The parasites that rely on this chemical cascade are members of the phylum Apicomplexa, which includes many important human and animal pathogens, such as:

About six years ago, researchers discovered that an unusual organelle of these parasites, called a plastid, had some striking resemblances to chloroplasts of plants. Plant plastids are the site for many essential biochemical functions, including the synthesis of compounds necessary for life such as certain amino acids and folate, which animals get from eating plants.

The plant-like shikimate pathway, which McLeod's team found in these parasites, consists of a series of seven biochemical reactions catalyzed by seven enzymes. This pathway results in the formation of chorismate, an essential building block of folate, certain amino acids, and ubiquinone, a molecule used in energy generation.

McLeod's team showed that glyphosate, by interfering with just one of those enzymes, could block the production of folate, inhibiting parasite growth and survival. Glyphosate proved effective against malaria strains that were resistant to an anti-malarial medicine, pyrimethamine, which interrupts folate processing at a different point. To confirm the finding, they demonstrated that these folate-starved parasites could be rescued, in the test tube, by giving them folate.

Using biochemical, genetic and chemotherapeutic techniques, McLeod's team demonstrated that these parasites all utilized the shikimate pathway. They isolated and sequenced the genes for one of the shikimate pathway enzymes from Toxoplasma and a malaria parasite and demonstrated the presence of four of the seven enzymes in parasites extracts.

Finally, they tested glyphosate in mice infected with lethal doses of T. gondii. Doses of glyphosate or pyrimethamine that could not protect the mice when used alone rescued infected mice when used in combination, even when the mice were allowed to eat diets with folate. "Since resistance to antimicrobial agents is a major problem in the treatment of malaria, we were pleased to find that combining medications in a logical way, to inhibit multiple enzymes in the pathway, enhanced their effect," said McLeod. "This emphasized the potential value of concomitantly targeting alternative enzymes along the same pathway."

Thanks to decades of herbicide research, the pathway is already well studied and several inhibitory compounds are available. The researchers have also begun looking for compounds that affect other enzymes and substrates in the pathway in novel ways.

In addition to the seven skikimate-pathway enzymes, these findings suggest that the enzymes responsible for other biochemical pathways which branch from the shikimate pathway, as well as other plant-like metabolic pathways, could also become drug targets.

Medications that target the shikimate pathway may also prove valuable against other disease-causing bacteria or fungi that rely on the pathway, such as Mycobacterium tuberculosis, which causes tuberculosis, Staphylococcus aureus, a common and increasingly drug-resistant cause of serious post-operative infections, and Pneumocystis carinii, the most frequent cause of pneumonia in patients with AIDS.

"Despite 50 years of intense research into anti-microbials, rationally selecting plant-like metabolic pathways to identify targets in Apicomplexans has not been tried previously," commented McLeod. Her team sought targets that were part of interelated metabolic pathways present in lower species but not present or very different in humans, a novel paradigm for rational drug discovery.

"The urgent need for better medications combined with recent recognition of similarities of Apicomplexan parasites and plants provided the rationale for the initial experiments," she added, "followed by multi-institutional collaborations of infectious disease specialists, parasitologists, biochemists, plant molecular biologists, and John Coggins, Ph.D., of Glasgow University, one of the world's experts in the shikimate pathway."

Additional authors of the paper include co-first authors Fiona Roberts, M.D., and Craig Roberts, M.D., who were research fellows in McLeod's laboratory and are now at the Universities of Glasgow and Strathclyde, Glasgow, Scotland; Jennifer Johnson, also working in McLeod's laboratory; Graham Coombs, Ph.D., and Tino Krell, Ph.D., University of Glasgow; Dennis Kyle, Ph.D., and Wil Milhous, M.D., Walter Reed Army Institute of Research in Washington, DC; Saul Tzipori, D.V.M., Tufts University, Boston; David Ferguson, Ph.D., Oxford University; and Debopam Chakrabarti, Ph.D., University of Central Florida, Orlando.

Funding support came from several sources including the National Institutes of Health, the World Health Organization, the Toxoplasmosis Research Institute, the Research to Prevent Blindness Foundation, the Wellcome Trust, a Glaxo-Jack Lectureship, the Michael Reese Physicians Research and Education Foundation, the Fulbright Scholars Program, and the European Union.
-end-


University of Chicago Medical Center

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.